Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,121 public trials 2,033 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)

NCT04880434

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Stanford University Palo Alto, California, United States
  • University California Los Angeles (UCLA) Santa Monica, California, United States
  • Sarah Cannon- Denver Denver, Colorado, United States
View all 40 locations
View Trial Details
Completed

Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC

NCT05510908

Conditions
AIDS Related Lymphoma, AIDS-Related Kaposi Sarcoma, AIDS-Related Malignancy, +58 more
Locations
  • Moores UCSD Cancer Center La Jolla, California, United States
  • George Washington University Cancer Center Washington D.C., District of Columbia, United States
  • University of Miami Miller School of Medicine-Sylvester Cancer Center Miami, Florida, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 16 locations
View Trial Details
Completed

Severe Asthma Research Program

NCT01606826

Conditions
Asthma, Bronchial Diseases, Hemic and Lymphatic Diseases, +15 more
Locations
  • University of California, San Francisco San Francisco, California, United States
  • Brigham & Women's Hospital Boston, Massachusetts, United States
  • Children's Hospital, Boston Boston, Massachusetts, United States
  • Washington University St Louis, Missouri, United States
View Trial Details
Completed

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

NCT04569032

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Stanford Cancer Center Stanford, California, United States
  • Stanford Hospital and Clinics, Investigational Drug Services Stanford, California, United States
View all 63 locations
View Trial Details

Related conditions